IN BRIEF: Frontier IP celebrates Amprologix fundraise
Frontier IP Group PLC - London-based intellectual property commercialisation firm - Portfolio company Amprologix raises GBP740,000 to accelerate development of its novel antibiotics for antimicrobial-resistant diseases. Funds will go towards completion of the pre-clinical development of lead candidate epidermicin NI01, which is being developed to treat Methicillin-resistant Staphylococcus aureus, MRSA. Expects phase 1 human clinical trials to start next year. Says Amprologix is also preparing for a Series A funding round. Investors in the recent fundraise included individuals and "angel-investor network" Plutus Investment Group LLP. Plutus' Venture Partner Rita Dobmeyer will be joining Amprologix's board as a non-executive director to support clinical development. Frontier says Amprologix is also in the early stages of developing an antibiotic to treat and prevent Clostridioides difficile or C difficile infections. Read More